XML 70 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating Activities:      
Net loss $ (178,297) $ (121,122) $ (95,419)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Depreciation and amortization 9,439 5,682 3,930
Amortization of premium (discount) on marketable securities, net 2,844 (825) (4,708)
Amortization and other changes in operating lease right-of-use assets 8,199 7,687 5,677
Gain on free shares (18) (63) (488)
Net (gain) loss on disposal of property and equipment (52) 222 68
Stock-based compensation 32,956 25,708 19,330
Adjustment of CIRM award liability related to the termination of the grant (6,427) 0 0
Net loss on lease termination 0 0 218
Net changes in operating assets and liabilities:      
Interest receivable 686 (353) (307)
Accounts receivable (789) 31,685 (32,236)
Prepaid expenses and other assets (7,175) (10,411) (6,660)
Accounts payable and other accrued liabilities (7,664) 10,703 (4,192)
Accrued compensation and employee benefits 373 6,877 4,129
Deferred revenues (84,202) 216,546 (35,693)
Long-term portion of lease liabilities (4,340) (3,761) (1,800)
Other non-current liabilities 1,216 1,300 3,749
Net cash (used in) provided by operating activities (233,251) 169,875 (144,402)
Investing Activities:      
Purchases of marketable securities (338,159) (570,779) (443,711)
Maturities of marketable securities 602,885 314,570 404,847
Sales of marketable securities 6,870 0 0
Purchases of property and equipment (23,278) (14,714) (20,675)
Purchase of additional Sangamo France shares (119) (704) (262)
Net cash provided by (used in) investing activities 248,199 (271,627) (59,801)
Financing Activities:      
Taxes paid related to net share settlement of equity awards (3,258) (765) (422)
Proceeds from exercise of stock options and restricted stock units 5,648 9,324 4,099
Net cash provided by financing activities 32,858 153,100 142,029
Effect of exchange rate changes on cash and cash equivalents, and restricted cash (263) (447) 184
Net increase (decrease) in cash, cash equivalents, and restricted cash 47,543 50,901 (61,990)
Cash, cash equivalents, and restricted cash, beginning of period 132,829 81,928 143,918
Cash, cash equivalents, and restricted cash, end of period 180,372 132,829 81,928
Supplemental cash flow disclosures:      
Property and equipment included in unpaid liabilities 1,535 4,569 2,114
Buy-out of non-controlling interest 943 0 0
Right-of-use assets obtained in exchange for lease obligations 10,418 1,333 31,291
At -the-market offering      
Financing Activities:      
Proceeds from issuance of common stock 27,099 0 0
Public Offering      
Financing Activities:      
Proceeds from issuance of common stock 0 0 136,308
Biogen Collaboration Agreement      
Financing Activities:      
Proceeds from issuance of common stock 0 142,526 0
Employee Stock      
Financing Activities:      
Proceeds from issuance of common stock $ 3,369 $ 2,015 $ 2,044